Gilead Publishes 2017 Year in Review

FOSTER CITY, Calif., May 2, 2018 — Gilead Sciences, Inc. today announced the release of its 2017 Year in Review, composed of its Annual Report and Corporate Social Responsibility report. The Year in Review provides a comprehensive view into the company’s achievements and highlights how it has continued to deliver on its mission to improve the lives of people living with life-threatening diseases.

Highlights of the 2017 report include:

  • Our Mission: Gilead’s product portfolio of more than 25 innovative medicines contains a number of category firsts, including complete treatment regimens for HIV and chronic hepatitis C virus infection available in once-daily single pills. Additionally, the strategic acquisitions of Kite Pharma, Inc. and Cell Design Labs, Inc. moved Gilead into a leadership position in the field of cell therapy.
  • Community Impact: Gilead provided approximately $400 million through various corporate giving programs to more than 2,000 nonprofit organizations around the world. In December, it announced the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative™, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.
  • Workplace: Gilead launched two new diversity-focused employee resource groups, Gileados, whose members are committed to embracing, fostering and sharing the multifaceted Latino culture within their professional communities, and GVET, which aims to recognize, appreciate and support veterans, active duty military and their families. In 2017, Gilead received a top score of 100 percent on the Human Rights Campaign 2018 Corporate Equality Index, a national benchmarking tool on corporate policies and practices related to lesbian, gay, bisexual and transgender employees.
  • Practices and Environment: Gilead introduced a Supplier Code of Conduct to integrate social, environmental and governance criteria into its procurement and supply-chain process. Since implementation, more than 100 of its strategic suppliers, representing more than $1 billion dollars in spend, have signed the Supplier Code of Conduct.

To read the full 2017 Year in Review, visit: www.gilead.com/yir2017

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.